Two of the three firms — Abbott, the maker of Similac, and Reckitt, which makes Enfamil — accounted for nearly 80% of the $4 billion baby-formula market in 2021. However, apparently neither they nor Gerber were on the Food and Drug Administration's list of "mission critical" inspections during the first year of the COVID-19 pandemic, per the AP.
"The FDA would have had more chances to catch these issues if they'd been inspecting during the pandemic," food safety specialist Sarah Sorscher told the AP.
Current law only requires inspections of baby formula facilities every three to five years, but the FDA had been conducting at least once-a-year visits until 2019. New legislation would require twice-yearly inspections.
The ongoing national shortage of baby formula began after one Abbott Nutrition plant in Michigan was shut down after four children got sick after consuming the company's powdered Similac.
An investigation later found unsanitary conditions at the plant , though the company maintains that the bacteria that caused the illnesses did not originate there.
The FDA told the AP it skipped about 15,000 inspections in the US because of pandemic safety measures, but it has caught up on 5,000 of those at a rate it says is ahead of schedule.
Get updates delivered to you daily. Free and customizable.
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. We strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation. Join us in shaping the news narrative together.
Comments / 0